Screening passengers as they arrive at UK airports is unlikely to prevent the importation of either SARS or influenza, finds a study published by the British Medical Journal.
In the event of a new SARS or influenza epidemic, air travel would represent the principal route of international spread. Although airport entry screening has been advocated, its benefit is currently unknown. Using the incubation periods for influenza and SARS, researchers at the Health Protection Agency estimated the proportion of passengers with latent infection who would develop symptoms during any flight to the United Kingdom.
For SARS, they found that the incubation period was too long to allow more than a small proportion of infected individuals to develop symptoms during a flight to the UK (0 percent to 3 percent for European flights and a maximum of 21 percent for the longest flights from East Asia).
Although influenza has a much shorter incubation period than SARS, the average predicted proportion of people infected with influenza and progressing during any flight was still less than 10 percent.
Because the proportion of individuals detected is highest from cities with the longest flight duration, screening passengers from the Far East and Australasia derives the most benefit. But, even then, the sensitivity for cities in these areas would still be low, explain the authors.
Early screening is unlikely to be effective in preventing the importation of either SARS or influenza, they conclude.
Although adopting a policy of quarantining all exposed passengers on the detection of a single case could substantially increase the benefit of entry screening, this still leaves the problem that the sensitivity of entry screening is low.
Source: British Medical Journal
Ensuring Safety and Comfort: The Urgent Need for Well-Fitted PPE in Health Care
April 5th 2024Personal protective equipment (PPE) stands as the first line of defense against infectious diseases in health care. Yet, the issue of ill-fitting PPE, especially for women, remains a significant challenge.
COVID-19 Harmonization: Balancing Risks and Benefits of CDC's Latest Move
March 11th 2024The CDC's recent decision to align recommendations for respiratory viruses, particularly COVID-19, has garnered support from the public and infectious disease societies. However, as the Infectious Diseases Society of America (IDSA) lends its backing to the CDC's harmonization efforts, concerns persist regarding the implications of this shift, especially considering the Omicron variant's unique characteristics and the ongoing challenges posed by COVID-19's multi-system impacts.
Voices of Resilience: Q&A With the Editor of "Corona City: Voices From an Epicenter"
March 1st 2024Step into the diverse and poignant world of "Corona City: Voices From an Epicenter" with editor Lorraine Ash, MA. In this insightful Q&A, learn about the origins of this remarkable anthology, the challenges faced in capturing raw, unfiltered narratives of the COVID-19 pandemic, and the lasting impact of these stories on readers and communities alike.
Rare Disease Day 2024: Spotlight on Rare Infectious Diseases
February 29th 2024Rare Disease Day on February 29, 2024, shines a global light on the impact of rare diseases, including rare infectious diseases. With a focus on early diagnosis and treatment access, this day highlights the struggles of those with rare conditions.